EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z Probiotic Sources: 15

Limosilactobacillus reuteri DSM 17938

Also called: Lactobacillus reuteri DSM 17938, L. reuteri DSM 17938, LR DSM 17938

Limosilactobacillus reuteri DSM 17938, formerly Lactobacillus reuteri DSM 17938, is a probiotic bacterial strain derived from L. reuteri ATCC 55730 by removing two plasmids that carried tetracycline and lincosamide resistance genes. Results here are for DSM 17938.

Category
Probiotic
Forms
Live bacteria given orally in trials (also notified to FDA for foods and infant formula); amounts stated in colony-forming units (CFU)
Strongest evidence
B Some positive trials
Reviewed
2026-10-30

Class 1 Well studied in people. A 2023 strain-specific meta-analysis included 12 RCTs (2,284 preterm infants) of L. reuteri DSM 17938 versus control, plus four non-randomized studies. [3]

Fact-checked 2026-10-30 · How this guide is made

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. EUTECNIQ sells no supplements today, and this page links to no product. Supplements can interact with medicines; ask a doctor or pharmacist before use, especially in pregnancy, while breastfeeding, before surgery or for a child.

Evidence

What research has studied

Grades describe the human evidence in the cited sources, not a recommendation. A means consistent randomized trials; X means good trials found no effect.

6 topics studied3 body areas · strongest grade B

A consistent trialsB some positive trialsC limited human evidenceD lab or animal onlyX no effect in good trials

From the table below Each topic in the table is placed on the part of the body it names, colored by its strongest grade. Tap an area, or open a line in the list, to see its topics. The map shows what was studied, not what Limosilactobacillus reuteri DSM 17938 does: a C or X area is not evidence of benefit. All 1,071 findings on one body map.
Topics studied for Limosilactobacillus reuteri DSM 17938, evidence grade and finding
Topic studiedGradeWhat the evidence shows
Crying and fussing in infants with colic (pooled individual data)BA 2018 individual-participant meta-analysis of 4 double-blind RCTs (345 infants) found 25.4 fewer minutes of crying/fussing at day 21 versus placebo; effects were large in breastfed infants but not significant in formula-fed infants. [4]
Infant colic in a community sample of breastfed and formula-fed infantsXIn a double-blind RCT of 167 infants in Melbourne, DSM 17938 (1 x 10^8 CFU/day for one month) did not reduce crying; the probiotic group cried or fussed 49 minutes more at 1 month. [5]
Acute gastroenteritis in childrenBA 2019 meta-analysis of 4 RCTs (347 children) found diarrhea shortened by 0.87 day versus placebo or no treatment; the authors note small effect sizes of limited clinical relevance and trial limitations. [7]
Preterm infants: necrotizing enterocolitis, late-onset sepsis and feedingCA 2023 meta-analysis of 12 RCTs (2,284 preterm infants) found less necrotizing enterocolitis (RR 0.57; 8 RCTs), less late-onset sepsis and faster full feeds, but no mortality difference; certainty was very low. [3]
Functional abdominal pain and functional constipation in childrenXA 2026 meta-analysis of single-strain RCTs found no significant benefit on responder rates in functional abdominal pain (5 RCTs, 302 children) or on stool frequency in functional constipation (5 RCTs, 276 children). [8]
Antibiotic-associated diarrhea in childrenCA 2026 systematic review of 3 RCTs (998 children analyzed) found lower risk with use for up to 21 days (2 RCTs; RR 0.50) but no effect with use of 14 days or less or with follow-up to 56 days. [9]

Main constituents: L. reuteri DSM 17938: daughter strain of ATCC 55730 without the two plasmids carrying the tet(W) and lnu(A) resistance genes; it lost the associated resistances [2]; Genus Limosilactobacillus: one of 23 novel genera proposed in the 2020 reclassification of Lactobacillus [1]

Amounts

Amounts studied and limits

Amounts used in research, not dosing advice. Products differ in form and strength; a clinician can advise on an individual dose.

  • Infant colic RCT (50 exclusively breastfed infants): 10^8 CFU/day for 21 days. [6]
  • Community colic RCT (167 infants): 1 x 10^8 CFU orally once daily for one month. [5]

No official upper intake level has been set.

Safety

Safety and side effects

  • Liver (NIH LiverTox)
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Pregnancy and breastfeeding
    Nothing found

    No published information found in the sources checked.

    Details and sources
  • Interactions with medicines
    1 listed

    Antibiotics (timing)

    Details and sources
  • Cancer evaluations (IARC, NTP)
    None found

    No IARC or NTP evaluation was found in the lists checked.

    Details and sources
  • FDA new dietary ingredient notifications
    None on FDA's list

    FDA does not approve dietary supplements. Each entry is one party's filing.

    Details and sources
  • Dose in official monographs
    Stated

    Health Canada probiotics monograph (April 24, 2026), Table 1 bacteria including Limosilactobacillus reuteri: 1.0 x 10^7 total CFU or more per day …

    Details and sources
  • In the 2023 preterm-infant review (12 RCTs, 4 non-randomized studies), L. reuteri DSM 17938 had no adverse effects. [3]
  • In the 50-infant colic RCT, no adverse events related to supplementation were observed and weight gain, constipation and regurgitation did not differ from placebo. [6]
  • FDA (2023, probiotics in general): administering probiotics to preterm infants may cause infection or invasive and potentially fatal disease; FDA reported one infant death and more than two dozen other adverse events. [10]
  • Health Canada's probiotics monograph: do not use if you have an immune-compromised condition (for example AIDS, lymphoma or long-term corticosteroid treatment). [11]
Interactions

Interactions

Known interactions of Limosilactobacillus reuteri DSM 17938
WithWhat happens
Antibiotics (timing)Health Canada's probiotics monograph directs taking the bacteria in its Table 1, which includes Limosilactobacillus reuteri, at least 2–3 hours before or after antibiotics. [11]

Tell a pharmacist or doctor about every supplement you take. All documented interactions in this hub.

Quality

Identity, quality and standardization

  • The parent strain ATCC 55730 carried plasmid-borne tet(W) and lnu(A) resistance genes; its beta-lactam resistance was linked to alterations in penicillin-binding protein genes and regarded as not transferable. [2]
  • Health Canada requires each strain to be identified by phenotype and genotype (including whole-genome strain characterization), absence of virulence to be shown, and at least 80% of the label-declared quantity to remain at the end of shelf life. [11]
  • US labels must list total microorganism weight, which can include live and dead cells; CFU may be listed voluntarily. [10]
Regulation

Regulatory status

  • Canada: Limosilactobacillus reuteri (formerly Lactobacillus reuteri) is listed in Health Canada's probiotics monograph (April 24, 2026) for general uses; labels must state the strain designation. [11]
  • US: No NDI notification naming L. reuteri DSM 17938 was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-30); NDI 87 (submitted 2000-07-06) and NDI 92 (amendment, 2000-10-02) name the parent strain ATCC 55730. FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [12]
  • US: FDA's GRAS Notice Inventory lists GRN 254 (L. reuteri strain DSM 17938 in foods at up to 10^9 CFU per serving; closed November 18, 2008) with the response 'FDA has no questions'. [13]
  • US: GRN 410 (L. reuteri strain DSM 17938 in powdered whey-based term infant formula at 10^6 to 10^8 CFU/g; closed March 26, 2012) also received 'FDA has no questions'. [14]
  • US: FDA states that under DSHEA it does not have the authority to approve dietary supplements before they are marketed; a firm is responsible for ensuring its products are not adulterated. [15]
Profile

Safety, quality and supply profile

Fourteen questions a careful buyer, formulator or clinician would ask, each answered only from a cited source (checked 2026-10-30). If our sources do not answer a question, we say so.

Compounds responsible

Compounds the sources name as the main or characteristic actives.

  • Live Limosilactobacillus reuteri DSM 17938 (formerly Lactobacillus reuteri DSM 17938) Probiotic bacterium (family Lactobacillaceae) [P1]

US status

What FDA's published records show. FDA does not approve dietary supplements.

  • No NDI notification naming L. reuteri DSM 17938 was found in FDA's published NDI list (dated July 9, 2026; checked 2026-10-30); NDI 87 (submitted 2000-07-06) and NDI 92 (amendment, 2000-10-02) name the parent strain ATCC 55730. FDA keeps no authoritative list of ingredients marketed before October 15, 1994. [P2]
  • FDA's GRAS Notice Inventory lists GRN 254 (foods, up to 10^9 CFU per serving; closed 2008-11-18) and GRN 410 (term infant formula; closed 2012-03-26) for L. reuteri strain DSM 17938, each with the response 'FDA has no questions'. [P3]

Cancer evaluations (IARC and NTP)

Evaluations name the exact material tested, which may differ from a supplement.

  • No IARC or NTP carcinogenicity evaluation of Limosilactobacillus reuteri DSM 17938 was found (IARC Monographs list of classifications and NTP technical reports checked 2026-10-30). [P6]

Liver (NIH LiverTox)

  • No published information found in the sources checked.

Interactions with medicines

  • Antibiotics (timing): Health Canada's probiotics monograph directs taking the bacteria in its Table 1, which includes Limosilactobacillus reuteri, at least 2–3 hours before or after antibiotics. [P5]

Alcohol

  • No published information found in the sources checked.

Interactions with other herbs and supplements

  • No published information found in the sources checked.

Adulteration and substitution

  • No published information found in the sources checked.

What a certificate of analysis should cover

Tests a quality specification for this material would include, with the reason for each.

  • Identity: at least one appropriate test or examination to verify the identity of each component that is a dietary ingredient (21 CFR 111.75(a)(1)(i)) — General Part 111 requirement for every dietary ingredient; FDA may exempt a firm only by granting a petition under 111.75(a)(1)(ii). [P8]
  • Strain identity by phenotype and genotype (genome-based comparison to type strains and whole-genome strain characterization) — Required by Health Canada's probiotics monograph for each live microorganism. [P5]
  • Absence of acquired antibiotic-resistance plasmids (tet(W), lnu(A)) — DSM 17938 was made by removing these plasmids from ATCC 55730; it lost the associated resistances. [P4]
  • Viable count (CFU) at end of shelf life — Health Canada requires at least 80% of the label-declared quantity at the end of shelf life. [P5]

Supply and conservation

  • No published information found in the sources checked.

Absorption in people

  • No published information found in the sources checked.

Formulations studied to change absorption

Human data only.

  • No published information found in the sources checked.

Dose in official monographs

As the monograph states it, for its jurisdiction; not personal advice.

  • Health Canada probiotics monograph (April 24, 2026), Table 1 bacteria including Limosilactobacillus reuteri: 1.0 x 10^7 total CFU or more per day (total from all live microorganisms in the product) for its general uses. [P5]

Pregnancy and breastfeeding

  • No published information found in the sources checked.

Sources for this profile

  1. Zheng J, et al. A taxonomic note on the genus Lactobacillus: description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae. Int J Syst Evol Microbiol 2020;70(4):2782-2858 (PMID 32293557), 2020-04. pubmed.ncbi.nlm.nih.gov
  2. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  3. FDA. GRAS Notice Inventory: GRN No. 254, Lactobacillus reuteri strain DSM 17938 (date of closure Nov 18, 2008), 2008-11-18. hfpappexternal.fda.gov
  4. Rosander A, Connolly E, Roos S. Removal of antibiotic resistance gene-carrying plasmids from Lactobacillus reuteri ATCC 55730 and characterization of the resulting daughter strain, L. reuteri DSM 17938. Appl Environ Microbiol 2008;74(19):6032-40 (PMID 18689509), 2008-10. pubmed.ncbi.nlm.nih.gov
  5. Health Canada, NNHPD. Natural health product monograph: Probiotics (date April 24, 2026), 2026-04-24. webprod.hc-sc.gc.ca
  6. IARC Monographs. List of Classifications: agents classified by the IARC Monographs, Volumes 1–142 (last updated 2026-07-23), 2026-07-23. monographs.iarc.who.int
  7. National Toxicology Program. Technical Reports (TR series index, TR-001 to TR-606; checked 2026-10-30), 2026-10-30. ntp.niehs.nih.gov
  8. eCFR. 21 CFR 111.75, What must you do to determine whether specifications are met? (up to date as of 10/23/2026), 2026-10-23. ecfr.gov
Sources

Sources

  1. Zheng J, et al. A taxonomic note on the genus Lactobacillus: description of 23 novel genera, emended description of the genus Lactobacillus Beijerinck 1901, and union of Lactobacillaceae and Leuconostocaceae. Int J Syst Evol Microbiol 2020;70(4):2782-2858 (PMID 32293557), 2020-04. pubmed.ncbi.nlm.nih.gov
  2. Rosander A, Connolly E, Roos S. Removal of antibiotic resistance gene-carrying plasmids from Lactobacillus reuteri ATCC 55730 and characterization of the resulting daughter strain, L. reuteri DSM 17938. Appl Environ Microbiol 2008;74(19):6032-40 (PMID 18689509), 2008-10. pubmed.ncbi.nlm.nih.gov
  3. Ang JL, et al. Limosilactobacillus reuteri DSM 17938 as a probiotic in preterm infants: an updated systematic review with meta-analysis and trial sequential analysis. JPEN J Parenter Enteral Nutr 2023;47(8):963-981 (PMID 37742098), 2023-11. pubmed.ncbi.nlm.nih.gov
  4. Sung V, et al. Lactobacillus reuteri to Treat Infant Colic: A Meta-analysis. Pediatrics 2018;141(1):e20171811 (PMID 29279326), 2018-01. pubmed.ncbi.nlm.nih.gov
  5. Sung V, et al. Treating infant colic with the probiotic Lactobacillus reuteri: double blind, placebo controlled randomised trial. BMJ 2014;348:g2107 (PMID 24690625), 2014-04-01. pubmed.ncbi.nlm.nih.gov
  6. Savino F, et al. Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. Pediatrics 2010;126(3):e526-33 (PMID 20713478), 2010-09. pubmed.ncbi.nlm.nih.gov
  7. Patro-Gołąb B, Szajewska H. Systematic review with meta-analysis: Lactobacillus reuteri DSM 17938 for treating acute gastroenteritis in children. An update. Nutrients 2019;11(11):2762 (PMID 31739457), 2019-11-14. pubmed.ncbi.nlm.nih.gov
  8. Quatrale G, et al. Limosilactobacillus reuteri DSM 17938 in pediatric functional abdominal pain disorders and functional constipation: a systematic review and meta-analysis of randomized controlled trials. J Pediatr Gastroenterol Nutr 2026 (online ahead of print Sep 29) (PMID 42811720), 2026-09-29. pubmed.ncbi.nlm.nih.gov
  9. Szajewska H, et al. Systematic review: Limosilactobacillus reuteri DSM 17938 for preventing antibiotic-associated diarrhoea in children. J Pediatr Gastroenterol Nutr 2026;82(3):781-789 (PMID 41486369), 2026-03. pubmed.ncbi.nlm.nih.gov
  10. NIH Office of Dietary Supplements. Probiotics: Fact Sheet for Health Professionals (Updated March 25, 2025), 2025-03-25. ods.od.nih.gov
  11. Health Canada, NNHPD. Natural health product monograph: Probiotics (date April 24, 2026), 2026-04-24. webprod.hc-sc.gc.ca
  12. FDA. Submitted 75-Day Premarket Notifications for New Dietary Ingredients (list dated July 9, 2026), 2026-07-09. fda.gov
  13. FDA. GRAS Notice Inventory: GRN No. 254, Lactobacillus reuteri strain DSM 17938 (date of closure Nov 18, 2008), 2008-11-18. hfpappexternal.fda.gov
  14. FDA. GRAS Notice Inventory: GRN No. 410, Lactobacillus reuteri strain DSM 17938 (date of closure Mar 26, 2012), 2012-03-26. hfpappexternal.fda.gov
  15. U.S. Food and Drug Administration. Questions and Answers on Dietary Supplements (content current as of 08/27/2026), 2026-08-27. fda.gov
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

More in probiotic: Akkermansia muciniphila (pasteurized) · Bacillus coagulans (Heyndrickxia coagulans) · Bifidobacterium animalis subsp. lactis BB-12 · Escherichia coli Nissle 1917 (EcN) · Lacticaseibacillus paracasei strain Shirota (LcS) · Lacticaseibacillus rhamnosus GG (LGG) · Lactiplantibacillus plantarum 299v · Probiotics · All entries A–Z · How to judge a supplement

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.